The Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), supported and funded by the Ministry of Education (MOE) and the National Research Foundation (NRF), provides an opportunity for Singapore to take a leading role in the world-wide charge against cancer using the most technologically advanced strategies, and to firmly position Singapore as one of the major centers for cancer biology and treatment in the Asian community and the world.
The institute is an anchor for research expertise in two broad programs: Cancer Stem Cells & Biology, and Experimental Therapeutics. These programs form expansive platforms for CSI Singapore’s focus on cancers in gastric, lung, hematologic malignancies and hepatocellular carcinoma, with special interest in areas endemic to Asian populations. In addition, the institute has also recently formed a working group in breast cancer looking at Asian phenotypes.
To that end, the leadership of the CSI Singapore would like to take the opportunity through the CSI Membership Program to broaden its network within the community of cancer researchers and clinician-scientists in Asia and the world.